A 54-year-old man with multiple endocrine neoplasia type 1 had previous history of parathyroid surgery and left thyroid lobectomy 5 years earlier, and was referred for recurrent hypoglycemic episodes. 68Ga-DOTATATE PET/CT had showed multiple lesions in the right lung, liver, and pancreas. Biopsy from pancreas revealed low-grade neuroendocrine neoplasia. After 2 fractions of 177Lu-DOTATATE therapy, the size of lesions and its activity reduced on the 68Ga-DOTATATE scan and the hypoglycemic episodes manifested every day have scaled down to 1 time over 1-year follow-up. Herein, we report a case of malignant insulinoma successfully treated with radiolabeled somatostatin receptor therapy using 177Lu-DOTATATE.
From the Departments of *Nuclear Medicine,
†General Surgery, and
‡Pathology, National Centre of Oncology, Baku, Azerbaijan.
Received for publication December 25, 2018; revision accepted January 5, 2019.
Conflicts of interest and sources of funding: This study was supported by funding from the Science Development Foundation under the President of the Republic of Azerbaijan, grant number EIF-2014-9(24)-KETPL-14/13/3. None declared to all authors.
Statement of human rights: Our study is a retrospective study. For this type of study, formal consent is not required.
Statement on the welfare of animals: This article does not contain any studies with human participants or animals performed by any of the authors.
Informed consent: This article does not contain any studies with individual participants performed by any of the authors.
Correspondence to: Fuad Novruzov, MD, PhD, National Centre of Oncology, Department of Nuclear Medicine, M. Xiyabani St, 137, AZ 1011, Baku, Azerbaijan. E-mail: firstname.lastname@example.org.